NEURORECOVERY GETS ORPHAN DRUG DESIGNATION.
Dr. Jay Meythaler, head of NRI's Scientific Advisory Board, commented, "We are encouraged by the orphan drug designation of 4-Aminopyridine for the treatment of chronic functional motor and sensory deficits from Guillain-Barre Syndrome. NRI's mission is to improve the functionality of patients suffering from peripheral neuropathies and this announcement supports our strategic goal to help patients suffering from peripheral neuropathies."
Edward Labry, chairman of NRI, commented, "NRI has achieved a major milestone by receiving orphan drug designation as this provides for seven years of market exclusivity in the United States for our proposed indication. Our lead product, Ampydin (IR), is an immediate release, oral administration version of 4-Aminopyridine (4-AP). We intend to develop Ampydin (IR) as a proposed treatment for a number of peripheral neuropathies."
About Neurorecovery Incorporated.
NRI is a biopharmaceutical company focused on treatment for peripheral neuropathies. Our lead product, Ampydin (IR), is an immediate release version of 4-Aminopyridine, or 4-AP. 4-Aminopyridine is currently on the FDA's compounding for compassionate use list for treatment of certain neuropathies and for spinal cord injury and MS. NRI is moving into a Phase III clinical trial with the proposed indication of 4-Aminopyridine for the treatment of chronic functional motor and sensory deficits resulting from Guillain-Barre Syndrome. The Phase IIa trial was partially funded by the National Institute of Disability, Rehab and Rehabilitation (NIDRR) and the Phase IIb trial was funded by a grant from the FDA Orphan Drug Office. The are a Delaware Corporation headquartered in Memphis, Tennessee.
For more information, visit http://www.neurorecoveryinc.com or call 901/537-2992.
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 1, 2007|
|Previous Article:||AVAA WORLD HEALTH LAUNCHES CLINICAL TRIAL FOR NEUROSKIN.|
|Next Article:||NVENTA UPDATES DEVELOPMENT STRATEGY ON HSPE7.|